Market Overview The cardiovascular drugs market is achieving significant milestones as heart failure therapies extend survival and improve quality of life for millions of patients with reduced and preserved ejection fraction. Sodium-glucose cotransporter-2 inhibitors, angiotensin receptor-neprilysin inhibitors, and soluble guanylate cyclase stimulators have fundamentally altered the therapeutic...